I Barişta. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Agranulocytosis/chemically inducedAntimetabolites, Antineoplastic/adverse effectsBone Marrow/drug effectsCytarabine/administration & dosageCytarabine/adverse effectsCytarabine/pharmacokineticsDelayed-Action PreparationsHumansInjections, SpinalMeningitis/drug therapyNeoplasms/complications
Substances： See more » Antimetabolites, AntineoplasticDelayed-Action PreparationsCytarabine
Year: 2000 PMID： 10784644 DOI： 10.1200/JCO.2000.18.9.2003
Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544